CD19 and diffuse large B-cell lymphoma: This retrospective real-world cohort study aims to describe the clinical outcomes and safety profile of both approved CD19-targeted CAR-T-cell therapies administered as standard of care to patients with DLBCL treated at a single regional center in Italy, with the goal of comparing these outcomes to those reported by high-volume academic centers.